BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares Sold by Decheng Capital LLC

Decheng Capital LLC reduced its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 50.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,000 shares of the company's stock after selling 20,000 shares during the period. BioNTech comprises 0.5% of Decheng Capital LLC's holdings, making the stock its 20th biggest position. Decheng Capital LLC's holdings in BioNTech were worth $1,821,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of BNTX. Banque Cantonale Vaudoise purchased a new position in BioNTech in the 1st quarter valued at $36,000. Allianz SE acquired a new stake in shares of BioNTech in the 4th quarter worth $90,000. Goodman Advisory Group LLC acquired a new stake in shares of BioNTech in the 1st quarter worth $105,000. Tower Research Capital LLC TRC increased its stake in shares of BioNTech by 61.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock worth $214,000 after acquiring an additional 713 shares during the last quarter. Finally, Probity Advisors Inc. increased its stake in shares of BioNTech by 8.5% in the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock worth $224,000 after acquiring an additional 154 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. The Goldman Sachs Group assumed coverage on BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price objective for the company. Bank of America cut their price objective on BioNTech from $127.00 to $126.00 and set a "buy" rating for the company in a research report on Wednesday, July 16th. Morgan Stanley lifted their target price on BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 10th. Finally, Leerink Partners set a $112.00 target price on BioNTech in a research report on Monday, June 2nd. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $136.58.

BioNTech Price Performance

BioNTech stock traded down $0.16 during trading hours on Friday, hitting $107.34. The stock had a trading volume of 840,683 shares, compared to its average volume of 598,465. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.18 and a quick ratio of 10.02. The stock has a market capitalization of $25.80 billion, a price-to-earnings ratio of -31.57 and a beta of 1.23. BioNTech SE Sponsored ADR has a 1-year low of $76.53 and a 1-year high of $131.49. The stock's fifty day moving average is $108.11 and its two-hundred day moving average is $106.27.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.